Systemic therapies for recurrent and/or metastatic salivary gland cancers

References

• Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Arch. Otolaryngol. Head Neck Surg.135(3), 451–457 (2006).
   Google Scholar
• Speight PM, Barrett AW. Salivary gland tumours. Oral Dis.8(5), 229–240 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes L, Eveson JW, Reichart P, Sidransky D.World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Barnes L, Eveson JW, Reichart PA, Sidransky D (Eds). IARC Press, Lyon, France (2005).
   Google Scholar
• Greene FL, Page DL, Fleming ID et al.AJCC Cancer Staging Handbook, 6th Edition. Springer, NY, USA 69–77 (2002).
   Google Scholar
• Witt RL. Major salivary gland cancer. Surg. Oncol. Clin. N. Am.13(1), 113–127 (2004).
   Google Scholar
• Harrison LB, Armstrong JG, Spiro RH et al. Postoperative radiation therapy for major salivary gland malignancies. J. Surg. Oncol.45(1), 52–55 (1990).
   Google Scholar
• Terhaard CH, Lubsen H, Rasch CR et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys.61(1), 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol.24(17), 2673–2678 (2006).
   PubMed Web of Science ®Google Scholar
• Licitra L, Marchini S, Spinazze S et al. Cisplatin in advanced salivary gland carcinoma. A Phase II study of 25 patients. Cancer68(9), 1874–1877 (1991).
   PubMed Web of Science ®Google Scholar
• Airoldi M, Pedani F, Succo G et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer91(3), 541–547 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert J, Li Y, Pinto HA et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck28(3), 197–204 (2006).
   PubMed Web of Science ®Google Scholar
• Piechocki M, Lonardo F, Ensley JF et al. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin. Cancer Res.8(3), 870–877 (2002).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357(17), 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357(17), 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Raguse JD, Gath HJ, Bier J et al. Docetaxel (Taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Oral Oncol.40(1), 5–7 (2004).
   Google Scholar
• Alberts DS, Manning MR, Coulthard SW et al. Adriamycin/cis-platinum-cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer47(4), 645–648 (1981).
   PubMed Web of Science ®Google Scholar
• Creagan ET, Woods JE, Schutt AJ et al. Cyclophosphamide, adriamycin, and cis-diamminedichloro-platinum in the treatment of advanced non-squamous cell head and neck cancer. Cancer52(11), 2007–2010 (1983).
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Fallon BG et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer60(12), 2869–2872 (1987).
   PubMed Web of Science ®Google Scholar
• Eisenberg MA. Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat. Rep.69, 319–321 (1985).
   Google Scholar
• Veenok AP, Tseng A, Meyers FJ et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J. Clin. Oncol.5(6), 951–955 (1987).
   Google Scholar
• Airoldi M, Fornari G, Pedani F et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res.20(5C), 3781–3783 (2000).
   PubMed Web of Science ®Google Scholar
• Laurie SA, Su YB, Pfister DG. Chemotherapy in the management of metastatic adenoid cystic carcinoma: a systematic review. J. Clin. Oncol.23, S520 (2005) (Abstract 5581).
   Google Scholar
• Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.95(5), 586–593 (2003).
   PubMedGoogle Scholar
• Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod. Pathol.16(12), 1224–1231 (2003).
   PubMed Web of Science ®Google Scholar
• Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod. Pathol.15(7), 687–691 (2002).
   PubMedGoogle Scholar
• Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol.23(3), 585–590 (2005).
   PubMed Web of Science ®Google Scholar
• Ochel HJ, Gademann G, Rocken C et al. Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res.25(5), 3659–3664 (2005).
   PubMed Web of Science ®Google Scholar
• Lin CH, Yen RF, Jeng YM et al. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck27(12), 1022–1027 (2005).
   Google Scholar
• Alcedo JC, Fabrega JM, Arosemena JR et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated cases. Head Neck26(9), 829–831 (2004).
   PubMedGoogle Scholar
• Guigay JM, Bidault F, Temam S et al. Antitumour activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a Phase II study. Proc. Am. Soc. Clin. Oncol.25, S508 (2007) (Abstract 6086).
   Google Scholar
• Faivre S, Raymond E, Casiraghi O et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol.23(25), 6271–6273 (2005).
   PubMed Web of Science ®Google Scholar
• Bruce IA, Slevin NJ, Homer JJ et al. Synergistic effects of imatinib (STI571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs16(7), 719–726 (2005).
   Google Scholar
• Slevin NJ, Mais KL, Bruce I et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoidcystic carcinoma – response assessed by FDG-PET scanning. J. Clin. Oncol. ASCO Ann. Meet. Proc.22(14), 5604 (2004).
   Google Scholar
• Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res.10(3), 944–946 (2004).
   PubMed Web of Science ®Google Scholar
• Dori S, Vered M, David R et al. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J. Oral Pathol. Med.31(8), 463–467 (2002).
   PubMedGoogle Scholar
• Nguyen LH, Black MJ, Hier M et al. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J. Otolarlyngol.32(5), 328–331 (2003).
   PubMedGoogle Scholar
• Skálová A, Stárek I, Vanecek T et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology42(4), 348–356 (2003).
   PubMedGoogle Scholar
• Dagrada GP, Negri T, Tamborini E et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology44(3), 301–302 (2004).
   Google Scholar
• Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a Phase II study. Oral Oncol.39(7), 724–727 (2003).
   PubMed Web of Science ®Google Scholar
• Prat A, Parera M, Reyes V et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck (2007) (Epub ahead of print).
   Google Scholar
• Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent Phase II studies with trastuzumab and gemcitabine. Clin. Adv. Hematol. Oncol.1(4), 226–228 (2003).
   Google Scholar
• Locati LD, Rinaldi G, Bossi P et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol.41(1), 97–98 (2005).
   PubMedGoogle Scholar
• Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck24(7), 632–636 (2002).
   PubMed Web of Science ®Google Scholar
• Chen CH, Liu BY, Wan JT et al. Expression of epidermal growth factor in salivary gland adenoid cystic carcinoma. Proc. Natl Sci. Counc. Repub. China B25(2), 90–96 (2001).
   PubMedGoogle Scholar
• Gibbons MD, Manne U, Carroll WR et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope111(8), 1373–1378 (2001).
   PubMedGoogle Scholar
• Katopodi E, Patsouris E, Papanikolaou V et al. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.95(3), 266–268 (2003).
   PubMedGoogle Scholar
• Fan CY, Melhem MF, Hosal AS et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor a in salivary duct carcinoma. Arch. Otolaryngol. Head Neck Surg.127(9), 1075–1079 (2001).
   PubMedGoogle Scholar
• Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J. Clin. Oncol. ASCO Ann. Meet. Proc.23(Suppl.16) 5532 (2005).
   Google Scholar
• Licitra LF, Locati LD, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. J. Clin. Oncol. ASCO Ann. Meet. Proc.24(Suppl. 18) 5547 (2006).
   Google Scholar
• Argiris A, Goldwasser MA, Burtness B et al. A Phase II of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. ASCO Ann. Meet. Proc.24(Suppl. 18) 5573 (2006).
   Google Scholar
• Agulnik M, Cohen EW, Cohen RB et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol.25(25), 3978–3984 (2007).
   PubMedGoogle Scholar
• Dori S, Trougouboff P, David R et al. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol.36(5), 450–453 (2000).
   Google Scholar
• Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J. Laryngol. Otol.111(12), 1186–1189 (1997).
   PubMed Web of Science ®Google Scholar
• Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen and progesterone receptors in salivary gland tumors: frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am. J. Clin. Pathol.119(6), 801–806 (2003).
   PubMed Web of Science ®Google Scholar
• Locati LD, Quattrone P, Bossi P et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann. Oncol.14(8), 1327–1328 (2003).
   PubMedGoogle Scholar
• van der Hulst RW, van Krieken JH, van der Kwast TH et al. Partial remission of parotid gland carcinoma after goserelin. Lancet344(8925) 817 (1994).
   PubMedGoogle Scholar